Rapid Micro Biosystems (RPID) Cash & Equivalents (2020 - 2026)

Rapid Micro Biosystems has disclosed Cash & Equivalents across 7 years of filings, most recently posting $13.8 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $13.8 million, up 13715.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.8 million (up 13715.0% YoY), and the FY2025 annual result was $100000.0, down 50.0% from the prior year.
• Cash & Equivalents came in at $13.8 million for Q1 2026 at Rapid Micro Biosystems, up from $100000.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $62.5 million in Q1 2022 to a low of $100000.0 in Q1 2023.
• The 5-year median for Cash & Equivalents is $13.8 million (2026), against an average of $15.6 million.
• Across the five-year window, Cash & Equivalents slumped 99.89% in 2022 and soared 22333.0% in 2024, its largest moves.
• Rapid Micro Biosystems' Cash & Equivalents stood at $200000.0 in 2022, then surged by 12042.5% to $24.3 million in 2023, then tumbled by 99.18% to $200000.0 in 2024, then slumped by 50.0% to $100000.0 in 2025, then surged by 13715.0% to $13.8 million in 2026.
• The last three Cash & Equivalents figures came in at $13.8 million (Q1 2026), $100000.0 (Q4 2025), and $18.9 million (Q3 2025), per Business Quant data.